We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+11.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$10.6B
AUM Growth
+$1.17B
(+12%)
Cap. Flow
+$3.01B
Cap. Flow
% of AUM
28.27%
Top 10 Holdings %
Top 10 Hldgs %
22.3%
Holding
850
New
52
Increased
273
Reduced
342
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$96.9M |
| 2 |
Merck
MRK
|
+$73.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$57.1M |
| 4 |
Illumina
ILMN
|
+$40.4M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$57.2M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$51.7M |
| 3 |
Kimberly-Clark
KMB
|
+$28.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$26.5M |
| 5 |
Arista Networks
ANET
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.77% |
| 2 | Technology | 20.35% |
| 3 | Consumer Discretionary | 9.49% |
| 4 | Communication Services | 7.69% |
| 5 | Financials | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Cboe Global Markets
CBOE
$31B
| $681K | 0.01% |
7,763
+1,215
| +19% | +$109K |
|
652
Datadog
DDOG
$95.6B
| $681K | 0.01% |
+6,670
| New | +$581K |
|
653
Rigel Pharmaceuticals
RIGL
$704M
| $672K | 0.01% |
28,000
-166,300
| -86% | -$4.08M |
|
654
Teleflex
TFX
$5.86B
| $672K | 0.01% |
1,975
-305
| -13% | -$113K |
|
655
Burlington
BURL
$23.4B
| $671K | 0.01% |
3,256
| – | – |
|
656
Western Digital
WDC
$184B
| $661K | 0.01% |
23,915
| – | – |
|
|
VG
657
DELISTED
Vonage Holdings Corporation
VG
| $655K | 0.01% |
+30,490
| New | +$338K |
|
658
Markel Group
MKL
$23.6B
| $654K | 0.01% |
672
-111
| -14% | -$113K |
|
659
Henry Schein
HSIC
$9.7B
| $652K | 0.01% |
11,095
+621
| +6% | +$39.8K |
|
660
Rogers Communications
RCI
$18.4B
| $650K | 0.01% |
16,431
| – | – |
|
|
ABMD
661
DELISTED
Abiomed Inc
ABMD
| $647K | 0.01% |
2,336
-855
| -27% | -$246K |
|
662
Lamb Weston
LW
$7.36B
| $646K | 0.01% |
9,746
| – | – |
|
663
Cincinnati Financial
CINF
$26.8B
| $643K | 0.01% |
8,251
-3,156
| -28% | -$244K |
|
664
Arch Capital
ACGL
$34.5B
| $637K | 0.01% |
21,786
-3,723
| -15% | -$113K |
|
665
Molson Coors Class B
TAP
$7.79B
| $637K | 0.01% |
18,989
| – | – |
|
666
Occidental Petroleum
OXY
$55.6B
| $623K | 0.01% |
62,197
+3,265
| +6% | +$46K |
|
667
Steel Dynamics
STLD
$36.2B
| $620K | 0.01% |
21,672
-4,286
| -17% | -$123K |
|
668
Elanco Animal Health
ELAN
$13.2B
| $610K | 0.01% |
21,840
-5,069
| -19% | -$128K |
|
|
WRK
669
DELISTED
WestRock Company
WRK
| $601K | 0.01% |
17,310
| – | – |
|
670
Jack Henry & Associates
JKHY
$11B
| $583K | 0.01% |
3,587
| – | – |
|
671
HEICO Corp Class A
HEI.A
$35.8B
| $581K | 0.01% |
6,549
-1,273
| -16% | -$107K |
|
672
Ulta Beauty
ULTA
$22.2B
| $575K | 0.01% |
2,569
| – | – |
|
|
AVLR
673
DELISTED
Avalara, Inc.
AVLR
| $574K | 0.01% |
4,510
| – | – |
|
|
RNAM
674
DELISTED
Avidity Biosciences
RNAM
| $563K | 0.01% |
20,000
| – | – |
|
675
Carnival Corporation Ltd
CCL
$38B
| $550K | 0.01% |
36,248
-154,504
| -81% | -$2.39M |
|
Similar funds
PCM
A
MGP
LF
BPA
MIM
SPIA
Candriam SCA's Q3 2020 Portfolio in Review
As of Q3 2020, Candriam SCA held 850 positions worth $10.6B, up 12% from $9.47B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $3.01B of net new capital in Q3 2020, opening 52 new positions and adding to 273 existing holdings. Its largest new stake was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $57.2M trimmed.
- Candriam SCA's largest Q3 2020 buy was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
- Candriam SCA added most to Amgen in Q3 2020, an estimated $96.9M increase.
- Candriam SCA's biggest Q3 2020 reduction was Apple, cutting an estimated $57.2M.
- Candriam SCA fully exited G1 Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $21.1M.
- Candriam SCA's ten largest holdings make up 22% of its $10.6B portfolio in Q3 2020.
- Candriam SCA opened 52 new positions and closed 48 in Q3 2020.
- Candriam SCA's portfolio value rose 12% quarter-over-quarter to $10.6B.
Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.